Tenax Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	118.76	97.57	94.85	9.79	2.12	5.58
Cash & Short-Term Investments	118.76	97.57	94.85	9.79	2.12	5.58
Cash Growth	6.56%	2.86%	868.66%	361.09%	-61.97%	-16.82%
Other Current Assets	4.42	6.66	1.84	1.89	1.08	0.11
Total Current Assets	123.18	104.23	96.69	11.68	3.21	5.69
Net Property, Plant & Equipment	-	-	-	-	0.19	0.29
Other Long-Term Assets	-	-	-	0	0.01	0.01
Total Assets	123.18	104.23	96.69	11.69	3.4	5.99
Accounts Payable	6.35	6.04	3.16	2.07	0.45	0.86
Accrued Expenses	2.14	1.12	1.54	1.01	0.78	0.7
Current Portion of Long-Term Debt	-	-	-	0.5	0.62	-
Total Current Liabilities	8.49	7.16	4.69	3.59	1.85	1.56
Long-Term Leases	-	-	-	-	0.06	0.18
Total Long-Term Liabilities	-	-	-	-	0.06	0.18
Total Liabilities	8.49	7.16	4.69	3.59	1.91	1.75
Common Stock	0	0	-	-	0	0
Additional Paid-in Capital	497.86	464.52	406.85	305.35	291.04	282.74
Retained Earnings	-383.17	-367.45	-314.86	-297.25	-289.54	-278.49
Shareholders' Equity	114.69	97.07	91.99	8.1	1.49	4.24
Total Liabilities & Equity	123.18	104.23	96.69	11.69	3.4	5.99
Total Debt	-	0	0	0.5	0.69	0.18
Net Cash (Debt)	118.76	97.57	94.85	9.29	1.44	5.4
Net Cash Growth	21.72%	2.86%	920.89%	547.38%	-73.42%	-16.51%
Net Cash Per Share	2.87	2.49	6.21	37.40	11.08	41.68
Book Value	114.69	97.07	91.99	8.1	1.49	4.24
Book Value Per Share	2.77	2.48	6.02	32.59	11.52	32.76
Tangible Book Value	114.69	97.07	91.99	8.1	1.49	4.24
Tangible Book Value Per Share	2.77	2.48	6.02	32.59	11.52	32.76

SEC Filings: 10-K · 10-Q